คาซิริวิแมบ/อิมดีวิแมบ (Thai Wikipedia)
Analysis of information sources in references of the Wikipedia article "คาซิริวิแมบ/อิมดีวิแมบ" in Thai language version.
refsWebsite
Global rank
Thai rank
1st place
1st place
49th place
87th place
low place
low place
low place
low place
5,225th place
7,482nd place
18th place
43rd place
low place
low place
low place
low place
615th place
1,105th place
406th place
1,266th place
7th place
41st place
5th place
17th place
low place
low place
60th place
938th place
17th place
302nd place
low place
low place
14th place
29th place
1,160th place
low place
low place
low place
archive.today
- "Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%". streetinsider.com. 12 April 2021. เก็บจากแหล่งเดิมเมื่อ 12 April 2021. สืบค้นเมื่อ 12 April 2021.
bbc.com
- Morelle, Rebecca (14 September 2020). "Antibody treatment to be given to Covid patients". BBC News Online. สืบค้นเมื่อ 14 September 2020.
- "Another life-saving Covid treatment found". BBC News (ภาษาอังกฤษแบบบริติช). 2021-06-16. สืบค้นเมื่อ 2021-10-04.
bioprocessintl.com
- Stanton, Dan (11 September 2020). "Manufacturing shift to Ireland frees up US capacity for Regeneron's COVID antibodies". BioProcess International.
businesswire.com
- "Genentech and Regeneron Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Combination for COVID-19" (Press release). Genentech. 19 August 2020. สืบค้นเมื่อ 8 June 2021 – โดยทาง Business Wire.
cipla.com
clinicaltrials.gov
- "Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19". ClinicalTrials. 3 September 2020. สืบค้นเมื่อ 14 September 2020.
cnbc.com
- "Roche and Regeneron link up on a coronavirus antibody cocktail". CNBC. 19 August 2020. สืบค้นเมื่อ 14 September 2020.
dailygazette.com
- Williams, Stephen (3 October 2020). "Experimental drug given to President made locally". The Daily Gazette.
doi.org
- Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, และคณะ (August 2020). "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies". Science. 369 (6506): 1014–1018. Bibcode:2020Sci...369.1014B. doi:10.1126/science.abd0831. PMC 7299283. PMID 32540904.
- Group, RECOVERY Collaborative; Horby, Peter W.; Mafham, Marion; Peto, Leon; Campbell, Mark; Pessoa-Amorim, Guilherme; Spata, Enti; Staplin, Natalie; Emberson, Jonathan R.; Prudon, Benjamin; Hine, Paul (2021-06-16). "Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial" (ภาษาอังกฤษ). pp. 2021.06.15.21258542. doi:10.1101/2021.06.15.21258542v1.
dw.com
- "Coronavirus: Germany to use new antibody-based drug". DW. 24 January 2021. สืบค้นเมื่อ 30 September 2021.
europa.eu
ema.europa.eu
- "EMA starts rolling review of REGN‑COV2 antibody combination (casirivimab / imdevimab)" (Press release). European Medicines Agency (EMA). 1 February 2021. สืบค้นเมื่อ 1 February 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "EMA reviewing data on monoclonal antibody use for COVID-19" (Press release). European Medicines Agency (EMA). 4 February 2021. สืบค้นเมื่อ 4 March 2021.
- "EMA issues advice on use of REGN-COV2 antibody combination (casirivimab / imdevimab)" (Press release). European Medicines Agency (EMA). 26 February 2021. สืบค้นเมื่อ 5 March 2021.
fda.gov
- "Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 21 November 2020. สืบค้นเมื่อ 21 November 2020.
บทความนี้รวมเอาเนื้อความจากแหล่งอ้างอิงนี้ ซึ่งเป็นสาธารณสมบัติ - "Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Casirivimab And Imdevimab" (PDF). U.S. Food and Drug Administration (FDA). June 2021.
- "Casirivimab And Imdevimab Emergency Use Authorization (EUA)" (PDF). U.S. Food and Drug Administration (FDA). July 2021.
- "FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19". U.S. Food and Drug Administration (FDA). 30 July 2021. สืบค้นเมื่อ 30 July 2021. บทความนี้รวมเอาเนื้อความจากแหล่งอ้างอิงนี้ ซึ่งเป็นสาธารณสมบัติ
gov.uk
- "Summary of Product Characteristics for Ronapreve". Medicines and Healthcare products Regulatory Agency (MHRA). 20 August 2021. สืบค้นเมื่อ 29 August 2021.
- "Regulatory approval of Ronapreve". Medicines and Healthcare products Regulatory Agency (MHRA). 20 August 2021. สืบค้นเมื่อ 29 August 2021.
- "First monoclonal antibody treatment for COVID-19 approved for use in the UK" (Press release). Medicines and Healthcare products Regulatory Agency (MHRA). 20 August 2021. สืบค้นเมื่อ 29 August 2021.
harvard.edu
ui.adsabs.harvard.edu
- Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, และคณะ (August 2020). "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies". Science. 369 (6506): 1014–1018. Bibcode:2020Sci...369.1014B. doi:10.1126/science.abd0831. PMC 7299283. PMID 32540904.
indianexpress.com
- "Roche's Antibody Cocktail launched in India at Rs 59,750/dose". The Indian Express. 25 May 2021. สืบค้นเมื่อ 30 September 2021.
indiatimes.com
timesofindia.indiatimes.com
- "India approves Roche/Regeneron antibody cocktail to treat Covid-19 – India News". The Times of India. 5 May 2021. สืบค้นเมื่อ 8 June 2021.
medrxiv.org
- Group, RECOVERY Collaborative; Horby, Peter W.; Mafham, Marion; Peto, Leon; Campbell, Mark; Pessoa-Amorim, Guilherme; Spata, Enti; Staplin, Natalie; Emberson, Jonathan R.; Prudon, Benjamin; Hine, Paul (2021-06-16). "Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial" (ภาษาอังกฤษ). pp. 2021.06.15.21258542. doi:10.1101/2021.06.15.21258542v1.
nih.gov
dailymed.nlm.nih.gov
- "Casirivimab injection, solution, concentrate Imdevimab injection, solution, concentrate REGEN-COV – casirivimab and imdevimab kit". DailyMed. สืบค้นเมื่อ 18 March 2021.
ncbi.nlm.nih.gov
- Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, และคณะ (August 2020). "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies". Science. 369 (6506): 1014–1018. Bibcode:2020Sci...369.1014B. doi:10.1126/science.abd0831. PMC 7299283. PMID 32540904.
pubmed.ncbi.nlm.nih.gov
- Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, และคณะ (August 2020). "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies". Science. 369 (6506): 1014–1018. Bibcode:2020Sci...369.1014B. doi:10.1126/science.abd0831. PMC 7299283. PMID 32540904.
npr.org
- Schneider, Avie (17 August 2021). "Texas Gov. Greg Abbott Tests Positive For The Coronavirus". NPR. สืบค้นเมื่อ 17 August 2021.
nytimes.com
- Thomas, Katie (2 October 2020). "President Trump Received Experimental Antibody Treatment". The New York Times. ISSN 0362-4331. สืบค้นเมื่อ 2 October 2020.
precisionvaccinations.com
- Hackett DW (3 October 2020). "8-Gram Dose of COVID-19 Antibody Cocktail Provided to President Trump". www.precisionvaccinations.com. เก็บจากแหล่งเดิมเมื่อ 3 October 2020.
prnewswire.com
- "Regeneron Reports Positive Interim Data with REGEN-COV Antibody Cocktail used as Passive Vaccine to Prevent COVID-19" (Press release). Regeneron Pharmaceuticals. 26 January 2021. สืบค้นเมื่อ 19 March 2021 – โดยทาง PR Newswire.
recoverytrial.net
- "RECOVERY COVID-19 phase 3 trial to evaluate Regeneron's REGN-COV2 investigational antibody cocktail in the UK". Recovery Trial. 14 September 2020.
- "RECOVERY trial finds Regeneron's monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response — RECOVERY Trial". www.recoverytrial.net. สืบค้นเมื่อ 2021-10-04.
regeneron.com
regeneron.com
- "Regeneron's COVID-19 Response Efforts". Regeneron Pharmaceuticals. สืบค้นเมื่อ 14 September 2020.
investor.regeneron.com
- "Regeneron announces U.S. government agreement to purchase additional COVID-19 antibody cocktail doses" (Press release). Tarrytown, New York: Regeneron. 12 January 2021. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-10-08. สืบค้นเมื่อ 2021-09-30.
reuters.com
- Kelland, Kate (14 September 2020). "Regeneron's antibody drug added to UK Recovery trial of COVID treatments". Reuters. สืบค้นเมื่อ 14 September 2020.
- "U.S. to buy 1.25 million additional doses of Regeneron's COVID-19 antibody cocktail". Reuters. 12 January 2021. สืบค้นเมื่อ 30 September 2021.
- "U.S. to buy 1.4 mln additional doses of Regeneron's COVID-19 therapy". Reuters. 14 September 2021. สืบค้นเมื่อ 30 September 2021.
roche.com
- "Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19". Roche (Press release). 20 July 2021. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-07-24. สืบค้นเมื่อ 29 August 2021.
science.org
- Kupferschmidt, Kai (16 June 2021). "Monoclonal antibodies cut risk of dying from COVID-19 – but only in some patients". Science.
A paper with the results will be made available on the medRxiv preprint server later today, the researchers say.
streetinsider.com
- "Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%". streetinsider.com. 12 April 2021. เก็บจากแหล่งเดิมเมื่อ 12 April 2021. สืบค้นเมื่อ 12 April 2021.
web.archive.org
- "Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19". Roche (Press release). 20 July 2021. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-07-24. สืบค้นเมื่อ 29 August 2021.
- Hackett DW (3 October 2020). "8-Gram Dose of COVID-19 Antibody Cocktail Provided to President Trump". www.precisionvaccinations.com. เก็บจากแหล่งเดิมเมื่อ 3 October 2020.
- "Regeneron announces U.S. government agreement to purchase additional COVID-19 antibody cocktail doses" (Press release). Tarrytown, New York: Regeneron. 12 January 2021. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-10-08. สืบค้นเมื่อ 2021-09-30.
who.int
- "On new recommendation for treatment of COVID-19 patients: WHO calls for equitable access to casirivimab and imdevimab for COVID-19". World Health Organization. 24 September 2021. สืบค้นเมื่อ 30 September 2021.
worldcat.org
- Thomas, Katie (2 October 2020). "President Trump Received Experimental Antibody Treatment". The New York Times. ISSN 0362-4331. สืบค้นเมื่อ 2 October 2020.